More patients who reported a serum magnesium level of ≤2.3 mg/dL significantly experienced dyslipidemia, higher level of hemoglobin, and lower serum sodium and tended to administrate beta-blockers, angiotensin-converting enzyme inhibitors (ACEIs) or angiotensin receptor blockers (ARBs), calcium channel blockers, and statin after admission [9]. Here, ACE is linked to metabolic syndrome.